A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02996110
Phase
PHASE2
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
    Specified Dose on Specified Days
  • Ipilimumab — BIOLOGICAL
    Specified Dose on Specified Days
  • Relatlimab — BIOLOGICAL
    Specified Dose on Specified Days
  • BMS-986205 — DRUG
    Specified Dose on Specified Days
  • BMS-813160 — DRUG
    Specified Dose on Specified Days

Study Details

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

Key Dates

Start date
Feb 2, 2017
Status verified
Nov 2022
Primary completion
Nov 23, 2021
Completion
Nov 23, 2021

Study Design

Enrollment
182 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Nivolumab + Ipilimumab
    Nivolumab + Ipilimumab
  • Experimental: Nivolumab + Relatlimab
    Nivolumab + Relatlimab
  • Experimental: Nivolumab + BMS-986205
    Nivolumab + BMS-986205
  • Experimental: Nivolumab + BMS-813160
    Nivolumab + BMS-813160 (CCR2/5 dual antagonist)

Primary Outcome Measure

Objective Response Rate (ORR) Per Investigator [ Time Frame: From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (assessed up to approximately 247 weeks) ]

Locations (20)

FacilityCityStateZIPSite coordinators
Local Institution - 0037New HavenConnecticut06520-
Local InstitutionTampaFlorida33612-9497-
Local Institution - 0031AugustaGeorgia30912-
Local Institution - 0006ChicagoIllinois60612-
Local Institution - 0007BaltimoreMaryland21287-
Dana Farber Cancer InstituteBostonMassachusetts02215-
Massachusetts General HospitalBostonMassachusetts02215-
Local Institution - 0011DetroitMichigan48201-
Local Institution - 0008St LouisMissouri63110-
Roswell Park Cancer InstituteBuffaloNew York14263-
Local Institution - 0005New YorkNew York10065-
Local Institution - 0043CharlotteNorth Carolina28204-
Local Institution - 0014ColumbusOhio43210-
Oregon Health & Science UniversityPortlandOregon97239-
Local Institution - 0002AllentownPennsylvania18103-
Hollings Cancer CenterCharlestonSouth Carolina29425-
Local Institution - 0025NashvilleTennessee37203-
Ut Southwestern Medical CenterDallasTexas75390-8570-
Local Institution - 0024CharlottesvilleVirginia22908-
University of Washington - Seattle Cancer Care AllianceSeattleWashington98109-

Find similar trials in New Haven, CT

By research site
Local Institution - 0037· New Haven, CTLocal Institution· Tampa, FLLocal Institution - 0031· Augusta, GALocal Institution - 0006· Chicago, ILLocal Institution - 0007· Baltimore, MDDana Farber Cancer Institute· Boston, MA

Related Studies